Did you know that just because a product says it has a certain amount of CBD per dose, it doesn’t mean your body is actually absorbing it? More CBD does NOT equal better results.
We often see CBD products with excessively high amounts of CBD, with no scientific data to support that that CBD is needed, or is even actually being delivered where and when your body needs it. Super-sizing is for hamburgers – not your medicine!
”Bioavailability” is extremely important in the scientific and medical community, as it pertains to how effective a medical product truly is.
In Pharmacology, bioavailability is the proportion of a drug or other substance (in this case CBD) that enters the blood circulation when introduced into the body and so is able to have an active effect. It is essential for a medical product to have high bioavailability to ensure the API (active pharmaceutical ingredient) reaches its intended target within the body.
When a product has high bioavailability, that means that all of the active ingredient are actually being absorbed into your bloodstream and creating the desired effect. This is why Tikva partners with Panaxia Pharmaceuticals to manufacture all our products – to ensure the highest level of bioavailability for our oils, tablets, and creams – and why our milligram dosing may seem lower in comparison to other brands. We do not need to super-size our products, because they actually work!
Unlike most CBD brands in the United States, our manufacturer, Panaxia, does specific testing on our products to ensure high bioavailability – This data validating the absorption, distribution, and metabolism of Tikva products is based on Pharmacokinetic (PK) Studies performed by Panaxia in Israel. Pharmacokinetics Studies are the study of how drugs are absorbed, distributed, metabolized, and excreted (Ratain & Plunkett, 2003). To our knowledge, no CBD brand in the United States has conducted these types of studies on their products.
Ratain MJ, Plunkett WK Jr. Principles of Pharmacokinetics. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK12815/